智翔金泰：GR1803注射液纳入优先审评品种名单

Core Viewpoint - The company announced that its product GR1803 injection has been included in the priority review list by the National Medical Products Administration's Drug Evaluation Center [1] Group 1 - GR1803 injection is a bispecific antibody drug independently developed by the company [1] - The drug targets BCMA and CD3 [1] - It is classified as a Class 1 therapeutic biological product [1]